Pharsight

1. Drug name - ABSORICA LD

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711	SUN PHARM	Low dose oral pharmaceutical composition of isotretinoin	May, 2035 (12 years from now)
US9700535	SUN PHARM	Oral pharmaceutical composition of isotretinoin	Aug, 2035 (12 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
8MG	CAPSULE;ORAL	Prescription
16MG	CAPSULE;ORAL	Prescription
20MG	CAPSULE;ORAL	Discontinued
24MG	CAPSULE;ORAL	Prescription
28MG	CAPSULE;ORAL	Discontinued
32MG	CAPSULE;ORAL	Prescription

2. Drug name - ACCRUFER

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802973	SHIELD TX	Crystalline forms of ferric maltol	Oct, 2035 (13 years from now)
CN107001310A	SHIELD TX	Crystalline Form Of Iron Maltol	Oct, 2035 (13 years from now)
CN107001310B	SHIELD TX	Crystalline Form Of Iron Maltol	Oct, 2035 (13 years from now)
EP3160951A1	SHIELD TX	Crystalline Forms Of Ferric Maltol	Oct, 2035 (13 years from now)
EP3160951B1	SHIELD TX	Crystalline Forms Of Ferric Maltol	Oct, 2035 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120	SHIELD TX	Dosage regimen of ferric trimaltol	Jan, 2035 (12 years from now)

Drugs and Companies using FERRIC MALTOL ingredient

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
30MG IRON	CAPSULE;ORAL	Prescription

3. Drug name - ADHANSIA XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500162	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10568841	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10507186	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10688060	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10292938	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US9974752	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10512612	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10111839	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10292939	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10512613	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)
US10449159	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (13 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
55MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
70MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
85MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

4. Drug name - ADRENALIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (12 years from now)
US9119876	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (12 years from now)
US10130592	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (12 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription

5. Drug name - AIRDUO DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415008 (Pediatric)	TEVA PHARM	Dry powder inhaler	Apr, 2035 (12 years from now)
US9066957 (Pediatric)	TEVA PHARM	Dry powder inhaler	Apr, 2035 (12 years from now)
US9782550	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US9782551	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US10918816	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (13 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

6. Drug name - AKYNZEO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9951016	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (13 years from now)
US10233154	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (13 years from now)
US10961195	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (13 years from now)
US10676440	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (13 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
300MG;EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

7. Drug name - ALECENSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350214	HOFFMANN-LA ROCHE	Preparation containing tetracyclic compound at high dose	Apr, 2035 (12 years from now)

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

8. Drug name - ALUNBRIG

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10385078	TAKEDA PHARMS USA	Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine	Nov, 2035 (13 years from now)
CN107108559B	TAKEDA PHARMS USA	5 - -N4-(2 -) (Dimethyl Phosphoryl) Phenyl] -N2-(2 - -4-(4 - (4 --- Yl)--- Piperazin - -1 - Piperidin - -1 - Yl] - Phenyl) - Pyrimidine - -2, 4 - - Diamine Crystalline Form	Oct, 2035 (13 years from now)
CN107108559A	TAKEDA PHARMS USA	5 - -N4-(2 - (- Dimethyl) Phenyl] -N2-(2-Methoxy - -4-[4 - (4-Methylpiperazine - -1 - Yl)--1 - Group]--2, 4-Diamine In Crystalline Form	Oct, 2035 (13 years from now)
EP3209647A1	TAKEDA PHARMS USA	Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine	Oct, 2035 (13 years from now)
EP3209647B1	TAKEDA PHARMS USA	Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine	Oct, 2035 (13 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

9. Drug name - ARAKODA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888558	60 DEGREES PHARMS	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec, 2035 (13 years from now)
US10342791	60 DEGREES PHARMS	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec, 2035 (13 years from now)

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription

10. Drug name - ARIKAYCE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9895385	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (12 years from now)
US10751355	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (12 years from now)
US10251900	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (12 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

11. Drug name - ARISTADA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526726	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (12 years from now)
US9452131	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (12 years from now)
US10238651	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (12 years from now)
US10813928	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

12. Drug name - ARISTADA INITIO KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154552	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (12 years from now)
US10849894	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (12 years from now)
US10688091	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (12 years from now)
US10016415	ALKERMES INC	Aripiprazole prodrug compositions	Sep, 2035 (12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
675MG/2.4ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

13. Drug name - ARMONAIR DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US9782550	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US10918816	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (13 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

14. Drug name - AXUMIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933147	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (13 years from now)
US10124079	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (13 years from now)
US10967077	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (13 years from now)
US10716868	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (13 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
9-221mCi/ML	SOLUTION;INTRAVENOUS	Prescription

15. Drug name - BAFIERTAM

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326965	BANNER LIFE SCIENCES	Controlled release fumarate esters	Feb, 2035 (12 years from now)
US9326947	BANNER LIFE SCIENCES	Controlled release fumarate esters	Feb, 2035 (12 years from now)
US10105335	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US9517209	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US9820960	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US10105337	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US9636319	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US9566259	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US10098863	BANNER LIFE SCIENCES	Fumarate esters	Feb, 2035 (12 years from now)
US9820961	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US10105336	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US9814691	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US9814692	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US9511043	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (12 years from now)
US9636318	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (12 years from now)
US10918616	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Jun, 2035 (12 years from now)
US10918617	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Aug, 2035 (12 years from now)
US10918615	BANNER LIFE SCIENCES	Fumarate esters	Aug, 2035 (12 years from now)
US10945985	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Aug, 2035 (12 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
95MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

16. Drug name - BALVERSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714	JANSSEN BIOTECH	Quinoxaline derivatives useful as FGFR kinase modulators	Mar, 2035 (12 years from now)

Drugs and Companies using ERDAFITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

17. Drug name - BIKTARVY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708342	GILEAD SCIENCES INC	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate	Jun, 2035 (12 years from now)
CN106459085A	GILEAD SCIENCES INC	(2R, 5S, 13Ar) -7, 9 - -10-((2, 4, 6-Trifluoro-Benzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A - -2, 5-Pyridine Methylene Bridge (1 ', 2 ': 4, 5] Pyridine [2, 1-B] [1, 3] * -8 - Sodium Phenolate	Jun, 2035 (12 years from now)
CN106459085B	GILEAD SCIENCES INC	An Anti-Hiv Compound And Its Crystal	Jun, 2035 (12 years from now)
EP3157932B1	GILEAD SCIENCES INC	Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate	Jun, 2035 (12 years from now)
EP3157932A1	GILEAD SCIENCES INC	Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate	Jun, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067	GILEAD SCIENCES INC	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate	Jun, 2035 (12 years from now)

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

18. Drug name - BREXAFEMME

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174074	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (12 years from now)
US10927142	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (12 years from now)

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription

19. Drug name - BUNAVAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188	BDSI	Abuse resistant transmucosal drug delivery device	Apr, 2035 (12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

20. Drug name - CALQUENCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083	ASTRAZENECA	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	Jan, 2035 (12 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription

21. Drug name - CINVANTI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953018	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US10500208	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US9974742	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (12 years from now)
US9808465	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US9974794	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US9561229	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US10624850	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (12 years from now)
US9974793	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (12 years from now)
US11173118	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (12 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
130MG/18ML (7.2MG/ML)	EMULSION;INTRAVENOUS	Prescription

22. Drug name - CYCLOPHOSPHAMIDE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342	EUGIA PHARMA SPECLTS	Formulations of cyclophosphamide liquid concentrate	Jun, 2035 (12 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/2.5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription

23. Drug name - DAYVIGO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652	EISAI INC	Compositions and methods for treating insomnia	Oct, 2035 (13 years from now)

Drugs and Companies using LEMBOREXANT ingredient

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

24. Drug name - DEFINITY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10022460	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (13 years from now)
CN107206111B	LANTHEUS MEDCL	Lipid Encapsulated Gas Microsphere Compositions And Related Methods	Dec, 2035 (13 years from now)
CN107206111A	LANTHEUS MEDCL	Gas Microsphere Composition Of Lipid Encapsulation And Related Method	Dec, 2035 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (13 years from now)

Drugs and Companies using PERFLUTREN ingredient

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
6.52MG/ML	INJECTABLE;INTRAVENOUS	Prescription

25. Drug name - EPIDIOLEX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11096905	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Oct, 2035 (13 years from now)
EP3206716B1	GW RES LTD	Use Of Cannabinoids In The Treatment Of Atonic Seizures In Lennox-Gastaut Syndrome	Oct, 2035 (13 years from now)
EP3206716A1	GW RES LTD	Use Of Cannabinoids In The Treatment Of Atonic Seizures In Lennox-Gastaut Syndrome	Oct, 2035 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709674	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US9956186	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10092525	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US9956183	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US9949937	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10111840	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10137095	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10603288	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10709671	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US9956184	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US9956185	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10849860	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10966939	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10709673	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (12 years from now)
US10918608	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (13 years from now)
US11065209	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (13 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: Use for the treatment of seizures in patients with dravet syndrome; use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with dravet syndrome; use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of focal seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; use for the treatment of seizures in patients with tuberous sclerosis complex; use for reducing seizure frequency in patients with tuberous sclerosis complex; Use for the treatment of seizures in patients with tuberous sclerosis complex

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
100MG/ML	SOLUTION;ORAL	Prescription

26. Drug name - ESKATA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980983	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US10493103	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US10729720	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US10098910	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US9675639	ACLARIS	Peroxide formulations and methods and applicators for using the same	Jul, 2035 (12 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
40%	SOLUTION;TOPICAL	Discontinued

27. Drug name - EVRYSDI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969754	GENENTECH INC	Compounds for treating spinal muscular atrophy	May, 2035 (12 years from now)
CN106459092B	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)
CN106459092A	GENENTECH INC	For Compound For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)
IN201647038542A	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)
IN334397B	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)
EP3143025B1	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)
EP3143025A1	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	May, 2035 (12 years from now)

Drugs and Companies using RISDIPLAM ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
0.75MG/ML	FOR SOLUTION;ORAL	Prescription

28. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Mar, 2035 (12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

29. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Mar, 2035 (12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

30. Drug name - EXEM FOAM KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494	GISKIT	Composition and method for medical imaging of body cavities	May, 2035 (12 years from now)

Drugs and Companies using AIR POLYMER-TYPE A ingredient

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

Strength	Dosage	Availability
10ML	FOAM;INTRAUTERINE	Prescription

31. Drug name - EXKIVITY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796712	TAKEDA PHARMS USA	Heteroaryl compounds for kinase inhibition	May, 2035 (12 years from now)
US10227342	TAKEDA PHARMS USA	Heteroaryl compounds for kinase inhibition	May, 2035 (12 years from now)
CN106559991B	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
CN106559991A	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
EP3409669B1	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
EP3157916A4	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
EP3409669A1	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
EP3157916B1	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)
EP3157916A1	TAKEDA PHARMS USA	Heteroaryl Compounds For Kinase Inhibition	May, 2035 (12 years from now)

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE;ORAL	Prescription

32. Drug name - FETROJA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10004750	SHIONOGI INC	Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof	Sep, 2035 (12 years from now)
CN106795176B	SHIONOGI INC	Salts Of Cephalosporin Derivatives, Crystalline Solid Thereof, And Process For Producing The Same	Sep, 2035 (12 years from now)
CN106795176A	SHIONOGI INC	Salt Of Cephalosporin Derivatives, Its Crystalline Solid And Its Manufacturing Method	Sep, 2035 (12 years from now)
EP3190115B1	SHIONOGI INC	Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same	Sep, 2035 (12 years from now)
EP3190115A4	SHIONOGI INC	Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same	Sep, 2035 (12 years from now)
EP3190115A1	SHIONOGI INC	Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same	Sep, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982	SHIONOGI INC	Preparation containing cephalosporin having a catechol moiety	Sep, 2035 (12 years from now)

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

33. Drug name - FINTEPLA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331	ZOGENIX INC	Control system for control of distribution of medication	Sep, 2035 (13 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 2.2MG BASE/ML	SOLUTION;ORAL	Prescription

34. Drug name - FIRVANQ KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959949	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)
US10959948	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)
US10959947	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)
US10493028	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)
US10688046	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)
US10959946	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (12 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Treatment: Treatment of c. difficile-associated diarrhea; treatment of staphylococcal enterocolitis; Treatment of staphylococcal enterocolitis; treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
EQ 25MG BASE/ML	FOR SOLUTION;ORAL	Prescription
EQ 50MG BASE/ML	FOR SOLUTION;ORAL	Prescription

35. Drug name - GENOSYL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051	VERO BIOTECH	Nitrogen dioxide storage device	Oct, 2035 (13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

Strength	Dosage	Availability
800PPM	GAS;INHALATION	Prescription

36. Drug name - HETLIOZ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10829465	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (12 years from now)
US10071977	VANDA PHARMS INC	Highly purifid pharmaceutical grade tasimelteon	Feb, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487	VANDA PHARMS INC	Method of treatment	Jul, 2035 (12 years from now)
US10179119	VANDA PHARMS INC	Method of treatment	Aug, 2035 (12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE;ORAL	Prescription

37. Drug name - HETLIOZ LQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10829465	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (12 years from now)
US10071977	VANDA PHARMS INC	Highly purifid pharmaceutical grade tasimelteon	Feb, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487	VANDA PHARMS INC	Method of treatment	Jul, 2035 (12 years from now)
US10179119	VANDA PHARMS INC	Method of treatment	Aug, 2035 (12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
4MG/ML	SUSPENSION;ORAL	Prescription

38. Drug name - ILLUCCIX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031	TELIX	Kit for radiolabelling	Jul, 2035 (12 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
6.7mCi/ML	POWDER;INTRAVENOUS	Prescription

39. Drug name - IMPOYZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334	PRIMUS PHARMS	Topical compositions comprising a corticosteroid	Mar, 2035 (12 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
0.025%	CREAM;TOPICAL	Prescription

40. Drug name - INLYTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202	PF PRISM CV	Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer	Feb, 2035 (12 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

41. Drug name - ISTURISA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680	RECORDATI RARE	Pharmaceutical dosage forms	Jul, 2035 (12 years from now)
US10709691	RECORDATI RARE	Pharmaceutical dosage forms	Oct, 2035 (13 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: Cushing's disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription

42. Drug name - JUBLIA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601	BAUSCH	Applicator	Apr, 2035 (12 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
10%	SOLUTION;TOPICAL	Prescription

43. Drug name - KAPSPARGO SPRINKLE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504655	SPIL	Capsule dosage form of metoprolol succinate	Jul, 2035 (12 years from now)
US9700530	SPIL	Capsule dosage form of metoprolol succinate	Jul, 2035 (12 years from now)

Drugs and Companies using METOPROLOL SUCCINATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 25MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 50MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

44. Drug name - KENGREAL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700575	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US9295687	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US10039780	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)
US9439921	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (12 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription

45. Drug name - KIMYRSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352	MELINTA THERAP	High purity oritavancin and method of producing same	Jul, 2035 (12 years from now)
IN201717005135A	MELINTA THERAP	High Purity Oritavancin And Method Of Producing Same	Jul, 2035 (12 years from now)
IN359618B	MELINTA THERAP	High Purity Oritavancin And Method Of Producing Same	Jul, 2035 (12 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1.2GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

46. Drug name - LENVIMA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11186547	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (12 years from now)
US10407393	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (12 years from now)
US10259791	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (12 years from now)
CN106660964A	EISAI INC	Quinoline Derivative With High Purity And Production Method Thereof	Aug, 2035 (12 years from now)
CN106660964B	EISAI INC	High Purity Quinoline Derivatives And Process For Producing The Same	Aug, 2035 (12 years from now)

Drugs and Companies using LENVATINIB MESYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 4MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription

47. Drug name - LOKELMA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9592253	ASTRAZENECA	Extended use zirconium silicate compositions and methods of use thereof	Oct, 2035 (13 years from now)
US10300087	ASTRAZENECA	Extended use zirconium silicate compositions and methods of use thereof	Oct, 2035 (13 years from now)

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
5GM/PACKET	FOR SUSPENSION;ORAL	Prescription
10GM/PACKET	FOR SUSPENSION;ORAL	Prescription

48. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661	SUNOVION RESP	Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element	Sep, 2035 (12 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

49. Drug name - MAVYRET

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48923	ABBVIE INC	Crystal forms	May, 2035 (12 years from now)
US9321807	ABBVIE INC	Crystal forms	Jun, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923 (Pediatric)	ABBVIE INC	Crystal forms	Nov, 2035 (13 years from now)
US9321807 (Pediatric)	ABBVIE INC	Crystal forms	Dec, 2035 (13 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: NA

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
50MG;20MG/PACKET	PELLETS;ORAL	Prescription

50. Drug name - NARCAN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629965	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9468747	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US10085937	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9480644	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9775838	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9561177	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9707226	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)
US9211253	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
2MG/SPRAY	SPRAY, METERED;NASAL	Discontinued
4MG/SPRAY	SPRAY, METERED;NASAL	Prescription

51. Drug name - NITYR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029	CYCLE PHARMS LTD	Pharmaceutical composition	Jan, 2035 (12 years from now)

Drugs and Companies using NITISINONE ingredient

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

52. Drug name - OBREDON

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9808431	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (13 years from now)
US10105324	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (13 years from now)
US9549907	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (13 years from now)

Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
200MG/5ML;2.5MG/5ML	SOLUTION;ORAL	Discontinued

53. Drug name - ONGENTYS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357468	NEUROCRINE	Medicaments for slowing Parkinson's disease	May, 2035 (12 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
50MG	CAPSULE;ORAL	Prescription

54. Drug name - ONPATTRO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11079379	ALNYLAM PHARMS INC	Methods of treating transthyretin (TTR) mediated amyloidosis	Aug, 2035 (12 years from now)
CN107106874B	ALNYLAM PHARMS INC	Method For Treating Transthyretin (Ttr) Mediated Amyloidosis	Aug, 2035 (12 years from now)
CN107106874A	ALNYLAM PHARMS INC	Method Of Treating Transthyretin (Ttr) Mediated Amyloidosis	Aug, 2035 (12 years from now)
EP3185957A4	ALNYLAM PHARMS INC	Methods Of Treating Transthyretin (Ttr) Mediated Amyloidosis	Aug, 2035 (12 years from now)
EP3185957A2	ALNYLAM PHARMS INC	Patisiran For Use In Treating Transthyretin Mediated Amyloidosis	Aug, 2035 (12 years from now)
EP3185957B1	ALNYLAM PHARMS INC	Patisiran For Use In Treating Transthyretin Mediated Amyloidosis	Aug, 2035 (12 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

55. Drug name - ORBACTIV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649352	MELINTA THERAP	High purity oritavancin and method of producing same	Jul, 2035 (12 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 400MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

56. Drug name - ORLADEYO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (12 years from now)
US10125102	BIOCRYST	Human plasma kallikrein inhibitors	Apr, 2035 (12 years from now)
CN106257976B	BIOCRYST	Human Plasma Kallikrein Inhibitors	Mar, 2035 (12 years from now)
CN106257976A	BIOCRYST	Human Plasma Kallikrein Inhibitor	Mar, 2035 (12 years from now)
EP3113772A4	BIOCRYST	Human Plasma Kallikrein Inhibitors	Mar, 2035 (12 years from now)
EP3113772A1	BIOCRYST	Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors	Mar, 2035 (12 years from now)
EP3113772B8	BIOCRYST	Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors	Mar, 2035 (12 years from now)
EP3113772B1	BIOCRYST	Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors	Mar, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (12 years from now)
US11230530	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (12 years from now)

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 110MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

57. Drug name - OTIPRIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220796	ALK ABELLO	Sterilization of ciprofloxacin composition	Jul, 2035 (12 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

Strength	Dosage	Availability
6% (60MG/ML)	INJECTABLE, SUSPENSION;OTIC	Prescription

58. Drug name - OXBRYTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447071	GLOBAL BLOOD THERAPS	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Feb, 2035 (12 years from now)
EP3102208A4	GLOBAL BLOOD THERAPS	Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde	Feb, 2035 (12 years from now)
EP3102208B1	GLOBAL BLOOD THERAPS	Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde	Feb, 2035 (12 years from now)
EP3102208A1	GLOBAL BLOOD THERAPS	Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde	Feb, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722502	GLOBAL BLOOD THERAPS	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Feb, 2035 (12 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG	TABLET;ORAL	Prescription

59. Drug name - OXLUMO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10612024	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US10612027	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US10478500	ALNYLAM PHARMS INC	Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression	Oct, 2035 (13 years from now)
CN108064154A	ALNYLAM PHARMS INC	Composition And Method For Inhibiting Hao1 (Hydroxy Acid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)
CN108064154B	ALNYLAM PHARMS INC	Composition And Method For Inhibiting Expression Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene	Oct, 2035 (13 years from now)
IN372206B	ALNYLAM PHARMS INC	Double-Stranded Rnai Agents And Compositions For Inhibiting Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)
IN201747014263A	ALNYLAM PHARMS INC	Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)
EP3204015A1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)
EP3204015A4	ALNYLAM PHARMS INC	Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)
EP3204015B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression	Oct, 2035 (13 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	SOLUTION;SUBCUTANEOUS	Prescription

60. Drug name - PEMAZYRE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267	INCYTE CORP	Substituted tricyclic compounds as FGFR inhibitors	Jan, 2035 (12 years from now)

Drugs and Companies using PEMIGATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
4.5MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
13.5MG	TABLET;ORAL	Prescription

61. Drug name - PEMFEXY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604990	EAGLE PHARMS	Crystalline forms of pemetrexed diacid and manufacturing processes therefor	Oct, 2035 (13 years from now)

Drugs and Companies using PEMETREXED ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
500MG/20ML (25MG/ML)	SOLUTION;INTRAVENOUS	Prescription

62. Drug name - PONVORY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220023	JANSSEN PHARMS	Dosing regimen for a selective S1P1 receptor agonist	Dec, 2035 (13 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

63. Drug name - PROAIR DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US9782550	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (12 years from now)
US10918816	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (13 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	POWDER, METERED;INHALATION	Prescription

64. Drug name - QBRELIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940177	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US9463183	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US10265370	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US10406199	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US10039800	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US9616096	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US9814751	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)
US11179434	AZURITY	Lisinopril formulations	Nov, 2035 (13 years from now)

Drugs and Companies using LISINOPRIL ingredient

Treatment: Treatment of myocardial infarction; method of treating hypertension; treatment of heart failure; method of treatment of heart failure; reduction of mortality in acute myocardial infarction; treatment of hypertension; acute myocardial infarction; Acute myocardial infarction; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; method of treatment of heart failure; treatment of heart failure; treatment of hypertension; method of treating hypertension; Treatment of hypertension; method of treating hypertension; treatment of heart failure; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; acute myocardial infarction; method of treatment of heart failure

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
1MG/ML	SOLUTION;ORAL	Prescription

65. Drug name - QULIPTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836	ABBVIE INC	Tablet formulation for CGRP active compounds	Jan, 2035 (12 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

66. Drug name - RHOFADE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751325	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)
US10335391	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)
US9974773	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (12 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

67. Drug name - RIOMET ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962336	SUN PHARM	Extended release suspension compositions	May, 2035 (12 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
500MG/5ML	FOR SUSPENSION, EXTENDED RELEASE;ORAL	Discontinued

68. Drug name - ROZLYTREK

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231965	GENENTECH INC	Molecules for administration to ROS1 mutant cancer cells	Feb, 2035 (12 years from now)
US10561651	GENENTECH INC	Methods for treating neuroblastoma	Feb, 2035 (12 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription
200MG	CAPSULE;ORAL	Prescription

69. Drug name - RUBRACA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987285	CLOVIS ONCOLOGY INC	High dosage strength tablets of rucaparib	Aug, 2035 (12 years from now)
US10130636	CLOVIS ONCOLOGY INC	High dosage strength tablets of rucaparib	Aug, 2035 (12 years from now)

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription
EQ 250MG BASE	TABLET;ORAL	Prescription
EQ 300MG BASE	TABLET;ORAL	Prescription

70. Drug name - SOLOSEC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335390	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US10857133	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US10849884	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US10682338	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US11000508	LUPIN	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (12 years from now)
US11020377	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US11000507	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)

Drugs and Companies using SECNIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis in adult women; treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
2GM/PACKET	GRANULE;ORAL	Prescription

71. Drug name - SOTYLIZE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724297	ARBOR PHARMS LLC	Sotalol compositions and uses of the same	Aug, 2035 (12 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
5MG/ML (5MG/ML)	SOLUTION;ORAL	Prescription

72. Drug name - SPINRAZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10436802	BIOGEN IDEC	Methods for treating spinal muscular atrophy	Sep, 2035 (12 years from now)

Drugs and Companies using NUSINERSEN SODIUM ingredient

Treatment: Treatment of type iii spinal muscular atrophy; treatment of spinal muscular atrophy; treatment of infantile-onset spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna

Dosage: SOLUTION;INTRATHECAL

Strength	Dosage	Availability
EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	SOLUTION;INTRATHECAL	Prescription

73. Drug name - SPRAVATO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869844	JANSSEN PHARMS	Methods for the treatment of depression	Sep, 2035 (12 years from now)
US11173134	JANSSEN PHARMS	Methods for the treatment of depression	Sep, 2035 (12 years from now)

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

Strength	Dosage	Availability
EQ 28MG BASE	SPRAY;NASAL	Prescription

74. Drug name - SPY AGENT GREEN KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10631746	NOVADAQ TECH	Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography	Aug, 2035 (12 years from now)

Drugs and Companies using INDOCYANINE GREEN ingredient

Treatment: Measuring time-varying change in blood in a tissue volume using modified beer-lambert law in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including minimally invasive, surgery

Dosage: POWDER;INTRAVENOUS, INTERSTITIAL

Strength	Dosage	Availability
25MG/VIAL	POWDER;INTRAVENOUS, INTERSTITIAL	Prescription

75. Drug name - SUBLOCADE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000520	INDIVIOR INC	Buprenorphine dosing regimens	Nov, 2035 (13 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
100MG/0.5ML (100MG/0.5ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
300MG/1.5ML (200MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

76. Drug name - SYMDEKO (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206877	VERTEX PHARMS INC	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases	Apr, 2035 (12 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG;75MG, 50MG	TABLET;ORAL	Prescription
150MG;150MG, 100MG	TABLET;ORAL	Prescription

77. Drug name - TABRECTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10596178	NOVARTIS PHARM	Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide	Jul, 2035 (12 years from now)
EP3172209A1	NOVARTIS PHARM	Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide	Jul, 2035 (12 years from now)
EP3172209B1	NOVARTIS PHARM	Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide	Jul, 2035 (12 years from now)

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

78. Drug name - TAGRISSO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020	ASTRAZENECA	Pharmaceutical compositions comprising AZD9291	Jan, 2035 (12 years from now)

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 80MG BASE	TABLET;ORAL	Prescription

79. Drug name - TAZVERIK

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10369155	EPIZYME INC	Method for treating cancer	Oct, 2035 (13 years from now)
US9889138	EPIZYME INC	Method for treating cancer	Oct, 2035 (13 years from now)
US10786511	EPIZYME INC	Method for treating cancer	Dec, 2035 (13 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

80. Drug name - TECFIDERA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10994003	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US10555993	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US10391160	BIOGEN INC	Dimethyl fumarate and vaccination regimens	Mar, 2035 (12 years from now)
US11007166	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (13 years from now)
US11129806	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (13 years from now)
US10959972	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (13 years from now)
US11007167	BIOGEN INC	Methods of treating multiple sclerosis	Nov, 2035 (13 years from now)

Drugs and Companies using DIMETHYL FUMARATE ingredient

Treatment: Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine; Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
120MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
240MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

81. Drug name - TIBSOVO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968595	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (12 years from now)
US10799490	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (12 years from now)
US10449184	SERVIER	Pharmaceutical compositions of therapeutically active compounds	Mar, 2035 (12 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); a method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; a method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory

Dosage: TABLET;ORAL

Strength	Dosage	Availability
250MG	TABLET;ORAL	Prescription

82. Drug name - TRIKAFTA (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10758534	VERTEX PHARMS INC	NA	Oct, 2035 (13 years from now)
CN107690281B	VERTEX PHARMS INC	Modulators Of Cystic Fibrosis Transmembrane Transduction Regulatory Factor	Oct, 2035 (13 years from now)
CN107690281A	VERTEX PHARMS INC	Cystic Fibrosis Transmembrane Transduction Regulatory Factor Regulator	Oct, 2035 (13 years from now)
EP3203840A1	VERTEX PHARMS INC	Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator	Oct, 2035 (13 years from now)
EP3203840B1	VERTEX PHARMS INC	Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator	Oct, 2035 (13 years from now)
EP3203840A4	VERTEX PHARMS INC	Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator	Oct, 2035 (13 years from now)

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG,37.5MG,25MG; 75MG	TABLET;ORAL	Prescription
100MG,75MG,50MG; 150MG	TABLET;ORAL	Prescription

83. Drug name - TYRVAYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597284	OYSTER POINT PHARMA	Dry eye treatments	Oct, 2035 (13 years from now)
US10456396	OYSTER POINT PHARMA	Dry eye treatments	Oct, 2035 (13 years from now)
US9504645	OYSTER POINT PHARMA	Pharmaceutical formulations for treating ocular conditions	Oct, 2035 (13 years from now)
US11224598	OYSTER POINT PHARMA	Methods of increasing lacrimal proteins	Oct, 2035 (13 years from now)
US9504644	OYSTER POINT PHARMA	Methods of increasing tear production	Oct, 2035 (13 years from now)
US9532944	OYSTER POINT PHARMA	Methods of improving ocular discomfort	Oct, 2035 (13 years from now)

Drugs and Companies using VARENICLINE TARTRATE ingredient

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;NASAL

Strength	Dosage	Availability
EQ 0.03MG BASE/SPRAY	SOLUTION;NASAL	Prescription

84. Drug name - UBRELVY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836	ALLERGAN	Tablet formulation for CGRP active compounds	Jan, 2035 (12 years from now)

Drugs and Companies using UBROGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

85. Drug name - UKONIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414773	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (12 years from now)
US9969740	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (12 years from now)
CN106661030B	TG THERAPS	Improved Form For Pharmaceutical Preparation Of Pi3K Inhibitors	May, 2035 (12 years from now)
CN106661030A	TG THERAPS	Improved Form For Pi3K Selective Inhibitor In The Pharmaceutical Formulation	May, 2035 (12 years from now)
IN328766B	TG THERAPS	Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations	May, 2035 (12 years from now)
IN201647042988A	TG THERAPS	Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations	May, 2035 (12 years from now)
EP3149000A1	TG THERAPS	Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations	May, 2035 (12 years from now)
EP3149000B1	TG THERAPS	Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations	May, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947244	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (12 years from now)

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

86. Drug name - VANCOMYCIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)
US10039804	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)
US11000567	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)
US10849956	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)

Drugs and Companies using VANCOMYCIN ingredient

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS, ORAL

Strength	Dosage	Availability
5GM/100ML (50MG/ML)	SOLUTION;INTRAVENOUS, ORAL	Prescription

87. Drug name - VANCOMYCIN HYDROCHLORIDE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)
US10039804	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)
US10849956	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (13 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

88. Drug name - VASOSTRICT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744239	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9750785	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9925233	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9925234	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9962422	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9968649	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9974827	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9981006	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US10010575	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9937223	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9687526	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9744209	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9375478	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)
US9919026	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (12 years from now)

Drugs and Companies using VASOPRESSIN ingredient

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
20UNITS/ML (20UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
20UNITS/100ML (0.2UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
40UNITS/100ML (0.4UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
60UNITS/100ML (0.6UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
200UNITS/10ML (20UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription

89. Drug name - VEKLURY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9724360	GILEAD SCIENCES INC	Methods for treating Filoviridae virus infections	Oct, 2035 (13 years from now)
US9949994	GILEAD SCIENCES INC	Methods for treating Filoviridae virus infections	Oct, 2035 (13 years from now)
CN107073005B	GILEAD SCIENCES INC	Method Of Treating A Virus Infection In A Filamentous Virus	Oct, 2035 (13 years from now)
CN107073005A	GILEAD SCIENCES INC	Method Of Treating Filamentous Virus Family Virus Infections	Oct, 2035 (13 years from now)
EP3212175A1	GILEAD SCIENCES INC	Methods For The Preparation Of Ribosides	Oct, 2035 (13 years from now)
EP3366295B1	GILEAD SCIENCES INC	Methods For Treating Filoviridae Virus Infections	Oct, 2035 (13 years from now)
EP3212174A1	GILEAD SCIENCES INC	Methods For Treating Filoviridae Virus Infections	Oct, 2035 (13 years from now)
EP3366295A1	GILEAD SCIENCES INC	Methods For Treating Filoviridae Virus Infections	Oct, 2035 (13 years from now)
EP3212175B1	GILEAD SCIENCES INC	Methods For The Preparation Of Ribosides	Oct, 2035 (13 years from now)
EP3212174B1	GILEAD SCIENCES INC	Methods For Treating Filoviridae Virus Infections	Oct, 2035 (13 years from now)

Drugs and Companies using REMDESIVIR ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription
100MG/20ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

90. Drug name - VELPHORO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624855 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	May, 2035 (12 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

Strength	Dosage	Availability
EQ 500MG IRON	TABLET, CHEWABLE;ORAL	Prescription

91. Drug name - VIEKIRA XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744170	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (12 years from now)
US10105365	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (12 years from now)
US9333204	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (12 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

92. Drug name - VITRAKVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10172861	BAYER HEALTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)
CN107428760B	BAYER HEALTHCARE	(S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form	Nov, 2035 (13 years from now)
CN107428760A	BAYER HEALTHCARE	(S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt	Nov, 2035 (13 years from now)
EP3218380A1	BAYER HEALTHCARE	Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate	Nov, 2035 (13 years from now)
EP3218380B1	BAYER HEALTHCARE	Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate	Nov, 2035 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782414	BAYER HEALTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 20MG BASE/ML	SOLUTION;ORAL	Prescription

93. Drug name - VITRAKVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10172861	BAYER HLTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)
CN107428760B	BAYER HLTHCARE	(S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form	Nov, 2035 (13 years from now)
CN107428760A	BAYER HLTHCARE	(S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt	Nov, 2035 (13 years from now)
EP3218380A1	BAYER HLTHCARE	Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate	Nov, 2035 (13 years from now)
EP3218380B1	BAYER HLTHCARE	Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate	Nov, 2035 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782414	BAYER HLTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)
US10285993	BAYER HLTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)
US10813936	BAYER HLTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Nov, 2035 (13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	CAPSULE;ORAL	Prescription
EQ 100MG BASE	CAPSULE;ORAL	Prescription

94. Drug name - VIVLODEX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649318	ZYLA	Formulation of meloxicam	Mar, 2035 (12 years from now)
US9808468	ZYLA	Formulation of meloxicam	Mar, 2035 (12 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam; management of osteoarthritis pain by administering 5 mg of meloxicam

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
5MG	CAPSULE;ORAL	Discontinued
10MG	CAPSULE;ORAL	Discontinued

95. Drug name - VYNDAMAX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9770441	FOLDRX PHARMS	Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole	Aug, 2035 (12 years from now)
EP3191461B1	FOLDRX PHARMS	Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole	Aug, 2035 (12 years from now)
EP3191461A1	FOLDRX PHARMS	Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole	Aug, 2035 (12 years from now)

Drugs and Companies using TAFAMIDIS ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
61MG	CAPSULE;ORAL	Prescription

96. Drug name - XHANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300229	OPTINOSE US INC	Nasal delivery devices	Jul, 2035 (12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.093MG	SPRAY, METERED;NASAL	Prescription

97. Drug name - XPOVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519139	KARYOPHARM THERAPS	Polymorphs of Selinexor	Aug, 2035 (12 years from now)
CN107072992B	KARYOPHARM THERAPS	Polymorphs Of	Aug, 2035 (12 years from now)
CN107072992A	KARYOPHARM THERAPS	Polymorph	Aug, 2035 (12 years from now)
EP3180331A1	KARYOPHARM THERAPS	Polymorphs Of Selinexor	Aug, 2035 (12 years from now)
EP3180331B1	KARYOPHARM THERAPS	Polymorphs Of Selinexor	Aug, 2035 (12 years from now)

Drugs and Companies using SELINEXOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

98. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912782	ANTARES PHARMA INC	Needle assisted injection administration of testosterone compositions	Feb, 2035 (12 years from now)
US10238662	ANTARES PHARMA INC	Needle assisted jet injection administration of testosterone compositions	Feb, 2035 (12 years from now)
US11191908	ANTARES PHARMA INC	Syringe shock absorber for use in an injection device	Oct, 2035 (13 years from now)
US9744302	ANTARES PHARMA INC	Needle assisted jet injection device having reduced trigger force	Nov, 2035 (13 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
50MG/0.5ML (50MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
75MG/0.5ML (75MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
100MG/0.5ML (100MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

99. Drug name - ZEGALOGUE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10442847	ZEALAND PHARMA	Glucagon analogues	Feb, 2035 (12 years from now)

Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	SOLUTION;SUBCUTANEOUS	Prescription

100. Drug name - ZERBAXA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10125149	CUBIST PHARMS LLC	Synthesis of cephalosporin compounds	Aug, 2035 (12 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

101. Drug name - ZINGO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358338	POWDER PHARMS	Particle cassettes and processes therefor	Apr, 2035 (12 years from now)
US9370622	POWDER PHARMS	Devices and methods for delivering particles	Sep, 2035 (13 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Treatment: Zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action

Dosage: SYSTEM;INTRADERMAL

Strength	Dosage	Availability
0.5MG	SYSTEM;INTRADERMAL	Prescription

102. Drug name - ZYNRELEF KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980886	HERON THERAPS INC	Compositions of a polyorthoester and an organic acid excipient	Apr, 2035 (12 years from now)
US9694079	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US10098957	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US9801945	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US10632199	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US10213510	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US11083730	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US11083797	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)
US10898575	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (12 years from now)

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

Strength	Dosage	Availability
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription

Pharsight

Drug Patents Expiring in 2035

1. Drug name - ABSORICA LD

2. Drug name - ACCRUFER

3. Drug name - ADHANSIA XR

4. Drug name - ADRENALIN

5. Drug name - AIRDUO DIGIHALER

6. Drug name - AKYNZEO

7. Drug name - ALECENSA

8. Drug name - ALUNBRIG

9. Drug name - ARAKODA

10. Drug name - ARIKAYCE KIT

11. Drug name - ARISTADA

12. Drug name - ARISTADA INITIO KIT

13. Drug name - ARMONAIR DIGIHALER

14. Drug name - AXUMIN

15. Drug name - BAFIERTAM

16. Drug name - BALVERSA

17. Drug name - BIKTARVY

18. Drug name - BREXAFEMME

19. Drug name - BUNAVAIL

20. Drug name - CALQUENCE

21. Drug name - CINVANTI

22. Drug name - CYCLOPHOSPHAMIDE

23. Drug name - DAYVIGO

24. Drug name - DEFINITY

25. Drug name - EPIDIOLEX

26. Drug name - ESKATA

27. Drug name - EVRYSDI

28. Drug name - EVZIO

29. Drug name - EVZIO (AUTOINJECTOR)

30. Drug name - EXEM FOAM KIT

31. Drug name - EXKIVITY

32. Drug name - FETROJA

33. Drug name - FINTEPLA

34. Drug name - FIRVANQ KIT

35. Drug name - GENOSYL

36. Drug name - HETLIOZ

37. Drug name - HETLIOZ LQ

38. Drug name - ILLUCCIX

39. Drug name - IMPOYZ

40. Drug name - INLYTA

41. Drug name - ISTURISA

42. Drug name - JUBLIA

43. Drug name - KAPSPARGO SPRINKLE

44. Drug name - KENGREAL

45. Drug name - KIMYRSA

46. Drug name - LENVIMA

47. Drug name - LOKELMA

48. Drug name - LONHALA MAGNAIR KIT

49. Drug name - MAVYRET

50. Drug name - NARCAN

51. Drug name - NITYR

52. Drug name - OBREDON

53. Drug name - ONGENTYS

54. Drug name - ONPATTRO

55. Drug name - ORBACTIV

56. Drug name - ORLADEYO

57. Drug name - OTIPRIO

58. Drug name - OXBRYTA

59. Drug name - OXLUMO

60. Drug name - PEMAZYRE

61. Drug name - PEMFEXY

62. Drug name - PONVORY

63. Drug name - PROAIR DIGIHALER

64. Drug name - QBRELIS

65. Drug name - QULIPTA

66. Drug name - RHOFADE

67. Drug name - RIOMET ER

68. Drug name - ROZLYTREK

69. Drug name - RUBRACA

70. Drug name - SOLOSEC

71. Drug name - SOTYLIZE

72. Drug name - SPINRAZA

73. Drug name - SPRAVATO

74. Drug name - SPY AGENT GREEN KIT

75. Drug name - SUBLOCADE

76. Drug name - SYMDEKO (COPACKAGED)

77. Drug name - TABRECTA

78. Drug name - TAGRISSO

availability in other generic markets.

Click on the highlighted region to filter.